At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
09995 REMEGEN
Pre-opening 07-02 09:06:32
78.200
+3.900
+5.25%
High78.200Low78.200Vol0.00
Open78.200D1 Closing74.300Amplitude0.00%
Mkt Cap44.07BTradable Cap16.31BTotal Shares563.61M
T/O0.00T/O Rate0.00%Tradable Shares208.58M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
Movement Alert｜RemeGen Falls 5.27% in Regular Trading, Massive Restricted Share Unlock Triggers Profit-Taking After Prior Session Surge
Market Focus  ·  06-30 10:35
Movement Alert｜RemeGen Falls 5.27% in Regular Trading, Massive Restricted Share Unlock Triggers Profit-Taking After Prior Session Surge
Hong Kong Market Rallies: Hang Seng Gains 1.57%, Biotech and Tech Sectors Lead Charge
Stock News  ·  06-29 16:58
Hong Kong Market Rallies: Hang Seng Gains 1.57%, Biotech and Tech Sectors Lead Charge
Hong Kong Market Midday Recap: Hang Seng Index Gains 2.12%, Reclaims 23,000 Level; Tech Index Up 3.68% with Broad-Based Gains
Deep News  ·  06-29 12:13
Hong Kong Market Midday Recap: Hang Seng Index Gains 2.12%, Reclaims 23,000 Level; Tech Index Up 3.68% with Broad-Based Gains
Hong Kong Market Midday Update: Hang Seng Index Climbs 2.12%, Biotech and Pharma Stocks Surge
Stock News  ·  06-29 12:13
Hong Kong Market Midday Update: Hang Seng Index Climbs 2.12%, Biotech and Pharma Stocks Surge
Movement Alert｜Remegen Rises 5.38% in Regular Trading, Lock-up Share Selling Restrictions and New Drug Approvals Drive Gains
Market Focus  ·  06-29 09:46
Movement Alert｜Remegen Rises 5.38% in Regular Trading, Lock-up Share Selling Restrictions and New Drug Approvals Drive Gains
Movement Alert｜RemeGen Rises 5.31% in Regular Trading, HK Biotech Sector Extends Rebound as Lock-Up Share Selling Restrictions Ease Overhang Concerns
Market Focus  ·  06-24
Movement Alert｜RemeGen Rises 5.31% in Regular Trading, HK Biotech Sector Extends Rebound as Lock-Up Share Selling Restrictions Ease Overhang Concerns
Movement Alert｜RemeGen Rises 5.02% in Regular Trading, Sector Rebounds as Lock-up Expiry Selling Pressure Eased by Regulatory Restriction
Market Focus  ·  06-23
Movement Alert｜RemeGen Rises 5.02% in Regular Trading, Sector Rebounds as Lock-up Expiry Selling Pressure Eased by Regulatory Restriction
Hong Kong Stocks Flat In Morning Trading
Dow Jones  ·  06-23
Hong Kong Stocks Flat In Morning Trading
HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%
Tiger Newspress  ·  06-23
HK Movers | Biotech Stocks Jump. InnoGen up over 17%; Alphamab, Hengrui Pharma, Laekna, Keymed Bio up Around 5%; Joinn, Remegen up About 4%
Remegen to Release 193 Million Locked Shares on July 1
Stock News  ·  06-22
Remegen to Release 193 Million Locked Shares on July 1
Movement Alert｜RemeGen Falls 5.33% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure
Market Focus  ·  06-22
Movement Alert｜RemeGen Falls 5.33% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure
RemeGen (SEHK:9995) Is Down 8.1% After Expanded Telitacicept Approvals in China Reshape Its Pipeline Narrative
Simply Wall St.  ·  06-21
RemeGen (SEHK:9995) Is Down 8.1% After Expanded Telitacicept Approvals in China Reshape Its Pipeline Narrative
RemeGen (SEHK:9995) Stock Could Be 39% Below Fair Value After Telitacicept Approvals
Simply Wall St.  ·  06-19
RemeGen (SEHK:9995) Stock Could Be 39% Below Fair Value After Telitacicept Approvals
REMEGEN Announces Board Re-Elections, Including Chairman and CEO
Stock News  ·  06-16
REMEGEN Announces Board Re-Elections, Including Chairman and CEO
Movement Alert｜RemeGen Falls 5.06% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure
Market Focus  ·  06-16
Movement Alert｜RemeGen Falls 5.06% in Regular Trading, HK Innovative Drug Sector Under Sustained Selling Pressure
Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress
Stock News  ·  06-12
Innovative Drug Stocks See Broad Gains as Sector's Outbound Licensing Activity Remains Robust, Supported by Policy Tailwinds and Commercialization Progress
Movement Alert｜RemeGen Rises 5.38% in Regular Trading, Dual Indication Approval for Core Drug Telitacicept Continues to Boost Sentiment
Market Focus  ·  06-12
Movement Alert｜RemeGen Rises 5.38% in Regular Trading, Dual Indication Approval for Core Drug Telitacicept Continues to Boost Sentiment
RemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains
Simply Wall St.  ·  06-10
RemeGen (SEHK:9995) Valuation Check After Recent Share Price Weakness And Multi Year Gains
BUZZ-RemeGen Shanghai shares jump most in 10 weeks on China nod for new drug marketing
Reuters  ·  06-09
BUZZ-RemeGen Shanghai shares jump most in 10 weeks on China nod for new drug marketing
New Drug from REMEGEN Gains Approval, Boosting A and H Share Prices; Pharmaceutical ETF Rebounds, Hong Kong Stock Connect Innovative Drug ETF Maintains Premium
Deep News  ·  06-09
New Drug from REMEGEN Gains Approval, Boosting A and H Share Prices; Pharmaceutical ETF Rebounds, Hong Kong Stock Connect Innovative Drug ETF Maintains Premium
No data available

Introduction

Company Name.
REMEGEN
Affiliated Markets:
SEHK
Listing Date:
--
Main Business:
RemeGen Co Ltd is a China-based company principally engaged in biopharmaceutical research, biopharmaceutical service, biopharmaceutical production and sale. The Company focuses on therapeutic antibody drugs such as antibody-drug conjugates (ADC), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company’s main products include telitacicept, disitamab vedotin, RC28-E and others. The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly operates its businesses in the domestic and overseas markets.
Issue price:
--